BACKGROUND: Early treatment is critical to reduce tuberculous meningitis (TBM)-related morbidity and mortality. Diagnosis based on cerebrospinal fluid (CSF) culture is impractical due to slow turn-around times, while microscopy has poor sensitivity. Enhanced detection methods are essential to guide early treatment initiation, especially in vulnerable young children. METHODS: We assessed the diagnostic accuracy of Genotype MTBDRplus® and Xpert MTB/RIF® assays on CSF collected from pediatric meningitis suspects prospectively enrolled at Tygerberg Hospital, Cape Town, South Africa. Fluorescent auramine-O microscopy, liquid culture for Mycobacterium tuberculosis, MTBDRplus® and Xpert MTB/RIF® assays were performed on all CSF samples. RESULTS: Of 101 meningitis suspects, 55 were diagnosed with TBM and 46 served as non-TBM controls. Using a pre-defined TBM case-definition as reference standard, sensitivities and specificities were 4% and 100% for fluorescent microscopy, 22% and 100% for culture, 33% and 98% for MTBDRplus®, 26% and 100% for Xpert MTB/RIF®, 22% and 100% for microscopy and/or culture combined and 49% and 98% for MTBDRplus® and Xpert MTB/RIF® combined. Culture, MTBDRplus® and Xpert MTB/RIF® combined performed best with 56% sensitivity and 98% specificity. CONCLUSION: Commercial nucleic-acid amplification tests performed on CSF revealed incrementally-improved diagnostic accuracy, providing rapid microbiological confirmation but cannot serve as a rule-out test.
INTRODUCTION
In 1993, the World Health Organization declared tuberculosis (TB) a global public health emergency 1 . Although some progress has been made, patient numbers in 2012 are essentially unchanged with an estimated 8.6 million new cases and 1.3 million deaths from TB worldwide 2 . In South Africa, the TB incidence has risen to 1000 new cases/100,000 population in 2012 2 , while large numbers of retreatment cases with a second or third episode of TB are not included in this figure 2, 3 .
Tuberculous meningitis (TBM) is the most devastating manifestation of TB and early treatment initiation is critical to optimize outcomes 4 . Confirmation of TBM diagnosis is challenging in young children due to the paucibacillary nature of disease and low cerebrospinal fluid (CSF) volumes available for diagnostic analysis 5 . Currently TBM confirmation requires visualization of acid-fast bacilli and/or a positive Mycobacterium tuberculosis (M.tuberculosis) culture from CSF. Direct microscopy for acid-fast bacilli in CSF is fast but has very low sensitivity (<20%) 6 whereas mycobacterial culture may take up to 42 days and has only slightly improved sensitivity [7] [8] [9] .
Several commercially available nucleic acid amplification tests (NAATs) have been developed for the rapid diagnosis of TB. The World Health Organization has endorsed the Xpert MTB/RIF® assay (Cepheid, Sunnyvale, CA, USA) for both smear microscopy-positive and -negative sputum specimens. Xpert simultaneously detects M.tuberculosis and susceptibility to rifampicin by amplification of the rpoB gene 10, 11 .
It is usable for a variety of liquid clinical samples 12, 13 . However, lower sensitivities attributed to low numbers of bacilli (59-62%), were obtained for CSF specimens 14, 15 .
The MTBDRplus® assay (Hain Lifescience GmbH, Nehren, Germany) version 1 is recommended for smear microscopy-positive specimens only 16, 17 , while version 2 of the assay can also be applied to smear microscopy-negative specimens, having similar sensitivity compared to Xpert MTB/RIF® 18, 19 . The MTBDRplus® is a line probe assay targeting the rpoB, katG and inhA genes, detecting M.tuberculosis, as well as rifampicin and isoniazid susceptibility. Although the MTBDRplus® assay version 2 has similar sensitivity and specificity to Xpert MTB/RIF® in smear microscopynegative specimens, Xpert MTB/RIF® detects M.tuberculosis quicker (under 2 hours vs 5 hours) and is a closed-tube system, with easier handling and decreasing contamination rates 20 .
In order to assess the utility of MTBDRplus® and Xpert MTB/RIF® to diagnose TBM in a clinical setting, alone and/or in combination with established diagnostic methods, we collected CSF samples from children with suspected meningitis in a setting where TBM is common.
METHODS
We conducted a prospective hospital-based study of all children clinically suspected of having meningitis.
Study Population and Setting
This study was conducted at Tygerberg Hospital, Cape Town, a major tertiary referral centre for Cape Town and surrounding areas. TBM is a common diagnosis among children diagnosed with meningitis 21 . Children were enrolled between January 2010
and March 2013. Inclusion criteria were 1) age 3 months to 13 years 2) clinical suspicion of meningitis 3) CSF sample collected for fluorescent auramine-O microscopy, M.tuberculosis culture, MTBDRplus® and Xpert MTB/RIF® assays and 4) written consent from the caregiver and assent if the child was older than 7 years and competent to do so. The study was approved by the Human Research Ethics Committee of Stellenbosch University, Cape Town, Western Cape, South Africa.
Clinical procedures
All patients underwent a comprehensive clinical evaluation. Routine investigations, including full blood count, basic biochemistry, HIV-screening, tuberculin skin test (TST), microbiological analysis of sputum or gastric washing (fluorescence microscopy for acid-fast bacilli and M.tuberculosis culture), bacterial blood culture, chest radiography and if clinically indicated, neuroimaging. Children were categorized as TBM, and non-TBM.
CASE DEFINITIONS Tuberculous meningitis (TBM)
A diagnosis of TBM was based on a uniform research case definition ( Probable TBM = total score of ≥12 when neuroimaging available = total score of ≥10 when neuroimaging unavailable Possible TBM = total score of 6-11 when neuroimaging available = total score of 6-9 when neuroimaging unavailable TBM-tuberculous meningitis, TB-tuberculosis, TST-tuberculin skin test, IGRA-interferon gamma-release assay, CSF-cerebrospinal fluid, CT-computed tomography, MRI-magnetic resonance imaging, US-ultrasound, AFB-acid-fast bacilli, NAAT-nucleic acid amplification test
Non-TBM
This included viral, fungal or bacterial meningitis (other than TBM) and cases without meningitis (normal CSF and/or confirmation of an alternative diagnosis). Viral meningitis was confirmed when a viral pathogen was identified in the CSF by polymerase chain reaction (PCR). Viral meningitis was considered probable with clinical evidence of acute meningitis and absence of any micro-organism on Gram stain of CSF and negative routine bacterial culture of CSF if antibiotics were not administered prior to the first lumbar puncture 24 . Bacterial or fungal meningitis was determined by the identification of a bacterial pathogen in the CSF using microscopy, culture or antigen detection methods. Probable bacterial meningitis was defined as clinical evidence of meningitis in addition to a suggestive CSF examination 25 .
CSF COLLECTION AND TESTING
CSF was obtained by lumbar puncture from all children included and the following investigations performed: appearance and color determination, differential cell count determination by standard methods, protein, glucose and chloride determination by standard methods, centrifugation with Gram stain and India ink examination on the deposit and culture of the centrifuged deposit on blood agar plates for pyogenic bacteria. When viral meningitis was suspected, PCR for cytomegalovirus, Epstein-Barr virus, enteroviruses, human herpesvirus-6, herpes simplex 1 & 2 and varicella zoster, was performed on CSF. Fluorescence microscopy was conducted using standardized auramine-O staining methods 26 .
M.tuberculosis culture
A volume of 0.5 ml of CSF was directly inoculated into a Mycobateria Growth Indicator Tube (MGIT; Becton Dickinson, Sparks, MD, USA) supplemented with 0.8 ml OADC (oleic acid, albumin, dextrose, catalase) containing PANTA (polymyxin B, amphotericin B, nalidixic acid, trimethoprim, azlocillin). The MGIT was placed into a BACTEC MGIT 960 instrument, incubated at 37°C. Flagged cultures were removed and the presence of acid-fast bacilli verified by Ziehl-Neelsen staining and microscopy. Bacterial contamination was excluded by placing one drop of culture on a blood agar plate with no growth after 48 hours incubation at 37°C. Specimens were determined negative if not flagged after 42 days of incubation.
GenoType MTBDRplus®
CSF samples were processed by the National Health Laboratory Service (NHLS) TB laboratory at Tygerberg Hospital. Samples were mixed by pipetting. The Genotype MTBDRplus® assays were used according to the manufacturer's instructions. The CSF volume analyzed was 0.5ml, with a 160 colony forming unit (CFU)/ml limit of detection. Quality control included a negative and positive control. Improvements in the DNA extraction from sonication and heat (version 1) to a chemical method (version 2), enabled its usage on smear microscopy-positive and -negative samples; the laboratory adopted version 2 in July 2012.
Xpert MTB/RIF®
An aliquot of 1 ml specimen was mixed with 2 ml of Xpert Sample Reagent (Cepheid), inverted 10 times, and incubated at room temperature. The inversion was repeated after 8 minutes and the incubation continued until a total duration of 15 minutes. After this, the mixture was completely transferred into an Xpert MTB/RIF cartridge, which was loaded into the GeneXpert instrument. All further processing, measuring and analysis steps happened automatically (GeneXpert Dx 4.0, Cepheid). Bacterial load was semi-quantitatively reported as very low, low, medium or high positive, with the presence or absence of resistance against rifampicin indicated separately 27 . The limit of detection is 100 CFU/ml 28 . Invalid results were repeated or excluded.
Statistical analysis
The study reporting conforms to the STARD guidelines for diagnostic accuracy reporting (www.stard-statement.org). Data analysis was performed using Statistical Package for the Social Sciences version 20 (SPSS Inc, Chicago, IL, USA). Frequencies were obtained for categorical clinical variables. Median and interquartile range was determined for continuous variables. Sensitivity, specificity, positive predictive value, negative predictive value and diagnostic odds ratio (DOR) was calculated comparing non-TBM to TBM. Categorical variables were compared using Fisher's exact test and continuous variables were compared using the Mann-Whitney U test. A p-value <0.05 was considered statistically significant.
RESULTS
In total 101 children with suspected meningitis met the inclusion criteria; 55 TBM and 46 "non-TBM". Of the TBM group, 13 patients had 'definite' TBM, 32 patients had 'probable' TBM and 10 patients had 'possible' TBM 22 . Among "non-TBM" patients, Table 2 .
Human immunodeficiency virus (HIV) co-infection was identified in 8 patients; 6 had neuroimaging suggestive of TBM. Of these, 5 had a positive TB contact within the last 12 months, 3 had a chest radiograph suggestive of pulmonary TB, 3 had bacteriologically-confirmed TBM and 1 had bacteriological confirmation of extraneural TB. Of the 2 non-TBM patients with HIV, 1 had confirmed pneumococcal meningitis and 1 patient did not have meningitis. IQR= interquartile range, HIV= Human Immunodeficiency Virus, TB= tuberculosis, GCS= Glasgow coma score, CSF= cerebrospinal fluid, AFB= acid-fast bacilli, CXR= Chest X-ray, PTB= pulmonary tuberculosis, CT= computed tomography, TBM-tuberculous meningitis *TB contact is defined as a history of recent close contact with a person with infectious tuberculosis within the past 1 year **Poor weight gain is defined as weight loss, or slower weight gain compared to age and gendermatched controls on the WHO weight for age charts
The diagnostic accuracy of the CSF tests against a TBM case definition and cultureconfirmed TBM is reflected in Table 3 and 4, respectively. When using a TBM case definition as the reference standard, both NAATs performed better than liquid culture and demonstrated some incremental value, although sensitivity remained sub-optimal. When using 'definite' TBM as the reference standard, the MTBDRplus® assay performed with 92% sensitivity and 98% specificity and Xpert MTB/RIF® assay performed with 39% sensitivity and 100% specificity in a small (n=13) group of children.
One "non-TBM" case tested positive with the Genotype MTBDRplus® assay version 2, but was negative on microscopy, culture and Xpert. The patient had a CSF picture suggestive of viral meningitis, and CSF PCR confirmation of Epstein-Barr virus, as well as normal brain computed tomography (CT). The patient improved clinically without any TB treatment and likely represented a false-positive test. Laboratory cross-contamination could not be ruled out with certainty, but no other cases of potential cross-contamination were detected. Table 3 . Sensitivity, specificity, predictive values and diagnostic odd ratios against a clinical TBM reference standard*** TBM= tuberculous meningitis, MGIT= Mycobateria Growth Indicator Tube, PPV= positive predictive value, NPV= negative predictive value, CI= confidence interval *** Uniform research case definition of Marais et al 22 .
An inhA mutation was detected in one patient, using the Genotype MTBDRplus® assay version 2, which is usually associated with low-level isoniazid resistance. This specific patient's treatment regimen included high dose isoniazid (20mg/kg), along with high dose rifampicin (20mg/kg), ethionamide (20mg/kg) and pyrazinamide (40mg/kg). As this patient defaulted treatment for 1 month, the total treatment period was 12 months. The patient was clinically followed up at 1-monthly intervals, with consistent weight-gain throughout. After 12 months of therapy the patient was considered cured, and discharged.
DISCUSSION
The main finding of this study is the incremental increase in diagnostic accuracy that can be achieved with commercial NAATs performed on CSF. Although both NAATs were superior to liquid culture, sensitivity remained low compared to a rigorous predefined clinical case definition. Combining any positive NAAT provided a sensitivity of 49%, which is insufficient to serve as a rule-out test and provides limited clinical guidance. However, a positive test provides useful microbiological confirmation with rapid turn-around times. When compared to culture-confirmed TBM, both NAATs The relatively poor correlation between NAATs and liquid culture may reflect the fact that NAATs detect DNA from viable and non-viable bacteria. Although every attempt was made to collect the CSF sample prior to the initiation of empiric therapy, some children were referred from outside centers and received initial treatment prior to CSF collection. This could explain the relatively low culture yields achieved, but it cannot explain why only a minority of cases with positive NAAT were both MTBDRplus® and Xpert MTB/RIF® positive. NAAT discrepancy may be due to random sampling variation in a pauci-bacillary CSF specimen. It has been suggested that at least 6 ml of CSF should be collected and concentrated to improve the diagnostic yield 30 . From our paediatric population we could only obtain a mean of 2.19 ml of CSF, and splitting these low volumes for four different tests could have resulted in false negative tests in instances where the bacterial load was below detection threshold. However, low CSF volumes are an unfortunate clinical reality in young children and in clinical practice all these tests will not have to be performed in parallel. Even with the low CSF volume obtained, the yield for the MTBDRplus® assay increased significantly with increased CSF volume.
The sensitivity of fluorescence microscopy (4%) was lower than that reported in the literature (10-20%) 6 and that of MGIT liquid culture was comparable (26% vs 22%) 31 .
There are no studies describing the use of the MTBDRplus® assay in CSF samples of either adults or children. The sensitivity of 33% (98% specificity) against a TBM case definition and sensitivity of 98% (98% specificity) against microbiologicallyconfirmed TBM, is encouraging and compares favorably with the performance on smear microscopy-negative sputa (19%) 32 . Xpert was 26% sensitive (100% specificity) against a TBM case definition and 39% sensitive (100% specificity) against microbiologically-confirmed TBM, but the use of this assay on CSF is not yet that well described. A pooled sensitivity of 70%; specificity of 97% for Xpert MTB/RIF® compared to liquid culture as a reference standard, was obtained in five studies in a recent meta-analysis 13, 14, 30, [33] [34] [35] . Concentration steps could have helped to reach the Xpert MTB/RIF® assay's detection threshold of approximately 100 bacteria/ml 13 .
Our clinical practice is to start anti-tuberculosis treatment on clinical suspicion prior to bacteriological confirmation. In settings with low TB incidence where experience with TBM is limited, treatment can be delayed with potentially dire consequences. In such settings NAATs offer improved CSF sensitivity, with good specificity, and a potential for same day diagnosis. The cost of the NAAT assays needs to be put into perspective to potential cost-savings by shorter hospital stay and better outcomes due to earlier initiation of treatment.
CONCLUSION
Commercial NAATs performed on CSF revealed incremental improvement in sensitivity, with specificity maintained. The best sensitivity was obtained with the combination of liquid culture and both NAATs, but there is not a massive gain when compared to both NAATs only. However, NAATs alone or in combination, cannot serve as a rule out test but can provide rapid microbiological confirmation. Cost-analysis needs to be performed comparing the expense of NAATs to the potential cost saving of early initiation of treatment and shorter hospital stay.
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